Skip to main content

Featured

Big Bank Earnings Wrap: What RBC and CIBC Reveal About Your Mortgage

  Royal Bank and CIBC reported record or near-record profits before the market opened Thursday, closing out a jam-packed bank earnings week that also included BMO, Scotiabank and National Bank. Beyond the headline numbers, though, the details tucked into these reports say a lot about where mortgage rates, lending standards and household credit stress are actually heading — and it's a more reassuring picture than a lot of the tariff-and-tension headlines this month might suggest. RBC: Record Profit, Credit Quality Barely Budged Royal Bank of Canada posted net income of $6.0 billion for the quarter ended July 31, up 11% from a year earlier and a record for the bank. Diluted earnings per share came in at $4.23, up 13% year-over-year, while return on equity climbed to 17.9%. The number worth watching for anyone with a mortgage isn't the profit line — it's the provision for credit losses (PCL), the money banks set aside for loans that might go bad. RBC's total PCL was $1.0 b...
Post a Comment
Read more

article

Labels

A New Dawn in Alzheimer’s Prevention: The AHEAD 3-45 Study


The AHEAD 3-45 study represents a beacon of hope for individuals like Tyson Haller, who, at 60, is determined to understand and possibly prevent the onset of Alzheimer’s—a disease that claimed his father. This groundbreaking clinical trial is testing lecanemab, an FDA-approved drug that has shown promise in slowing Alzheimer’s progression in its early stages. The optimism surrounding this trial is palpable, as it could herald a new era where Alzheimer’s is as manageable as Type 2 diabetes.

  • Family History’s Weight: Haller’s participation is driven by his family’s battle with Alzheimer’s, highlighting the emotional and proactive steps taken by those at risk.
  • Lecanemab’s Potential: The trial’s focus on lecanemab, a drug targeting beta amyloid plaques in the brain, offers a glimpse into a future where early intervention could significantly slow the disease’s impact.
  • Scientific Debate: Despite the excitement, there’s a scientific debate about beta amyloid’s role in Alzheimer’s, underscoring the complexity of finding a definitive treatment.
  • Awaiting Results: With the AHEAD and TRAILBLAZER prevention trials running until 2027 and 2029, patients, doctors, and researchers are in a state of limbo, hopeful yet uncertain of the long-term outcomes.

This study not only represents a potential turning point in Alzheimer’s research but also embodies the personal stories of those fighting to preserve their memories and identities against this relentless disease.

Labels:

Comments

Post a Comment